| 前收市價 | 1.9370 |
| 開市 | 1.9200 |
| 買盤 | 1.8550 x 無 |
| 賣出價 | 2.0200 x 無 |
| 今日波幅 | 1.9100 - 1.9480 |
| 52 週波幅 | 1.4600 - 3.8600 |
| 成交量 | |
| 平均成交量 | 0 |
| 市值 | 無 |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | 無 |
| 業績公佈日 | 2024年5月07日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
ZacksPoseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 25% and 99.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
InvestorPlaceBiotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
The article embarks on a transformative journey through the biotech frontier, where the listed companies stand as titans reshaping healthcare norms. The first one’s strategic collaboration with a multinational healthcare giant propels financial strength, unlocking accelerated milestones in key programs. The second one takes center stage with “Barzolvolimab,” a revolutionary monoclonal antibody targeting mast cell activity, showcasing versatility in treating various diseases. Meanwhile, the third
InvestorPlaceBiotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three companies are emerging as pioneers, guiding the world into a new era of therapeutic possibilities. Imagine a cancer treatment so versatile and safe that it has the potential to redefine how we combat this relentless disease. The first one, Allogeneic CAR-T therapy, is a beacon of hope in oncology. It
